No Data
Cleo Diagnostics Issues 250,000 New Shares Under Corporations Act Exemption
CLEO Diagnostics Seeks Quotation for Additional ASX Shares
Cleo Diagnostics Outlines US Commercialization Strategy for Ovarian Cancer Test Ahead of FDA Clearance
Cleo Diagnostics Hits Key U.S. Trial Milestone and Locks In Platform for Ovarian Cancer Test
Cleo Diagnostics Starts Manufacturing, Development Program for Ovarian Cancer Test Kit Production; Shares Up 8%
Cleo Diagnostics Achieves Recruitment Target for US Pre-Surgical Ovarian Cancer Test Trial